Risuteganib: Risks & Legal Status

Critical Safety Information#

Risuteganib is an investigational drug in clinical development by Allegro Ophthalmics. It is not approved by any regulatory authority and is available only through clinical trials. The information on this page is for educational purposes only.

Risk Assessment#

Clinical Development Risk#

While Phase 2a results were statistically significant and clinically meaningful, several important caveats apply:

• Small sample size: Only 40 patients were randomized, limiting statistical power and the ability to detect uncommon adverse events
• Short follow-up: The longest observation period is 28 weeks
• Crossover design: The sham group crossed over to risuteganib at week 16, limiting long-term placebo comparison
• Phase 2 to approval attrition: Historical data shows approximately 60-70% of drugs with positive Phase 2 results fail to gain approval

Procedural Risks#

Intravitreal injection is an invasive procedure with known risks:

Disease Progression#

Patients in clinical trials receiving sham injections may experience continued vision loss during the study period. The sham-controlled design, while scientifically necessary, means some patients do not receive active treatment for the duration of the sham period.

Regulatory Status#

Estimated Development Timeline#

Based on publicly available information:

• Phase 2b/3: Currently enrolling/ongoing
• Potential regulatory submission: Dependent on Phase 2b/3 results
• Potential approval: Cannot be estimated until Phase 2b/3 data are available

Risk Assessment Context#

Risuteganib belongs to the Healing category of research peptides. Risk assessment for Risuteganib should consider both the compound-specific risks identified in clinical research and the broader regulatory environment. Researchers and healthcare providers should evaluate these risks in the context of the specific patient population and therapeutic indication.

Risk Categories#

The following risk categories have been identified for Risuteganib based on available evidence and regulatory assessments:

Investigational Status#

Risuteganib is an investigational drug that has not been approved by any regulatory authority. Phase 2a results are promising but require confirmation in the ongoing Phase 2b/3 trial. The historical success rate from Phase 2 to approval is approximately 30-40%.

Intravitreal Injection Risks#

Intravitreal injection carries inherent procedural risks including endophthalmitis (intraocular infection, approximately 0.02-0.05% per injection), retinal detachment, vitreous hemorrhage, and elevated intraocular pressure. These risks are independent of the drug being injected.

Limited Long-Term Data#

The longest clinical follow-up for risuteganib is 28 weeks from the Phase 2a trial. Long-term efficacy durability and safety with chronic dosing every 12 weeks are unknown. The Phase 2b/3 trial will provide 52-week data.

Small Study Population#

Only 40 patients were enrolled in the Phase 2a trial. This small sample size limits the ability to detect uncommon adverse events and may overestimate treatment effect sizes.

Regulatory Status by Jurisdiction#

The regulatory and legal status of Risuteganib varies by country and jurisdiction. Researchers should verify current regulations before acquiring or using this compound.

Regulatory classifications can change. Researchers are responsible for complying with all applicable laws and regulations in their jurisdiction.

Important Warnings#

The following warnings apply to Risuteganib:

• Risuteganib is an investigational drug available only through clinical trials. It cannot be prescribed, purchased, or obtained outside of approved clinical studies.
• Intravitreal injection is a medical procedure that must be performed by a qualified retinal specialist under sterile conditions. Self-administration is not possible and would be extremely dangerous.
• Phase 2a results, while promising, are based on 40 patients followed for 28 weeks. These results may not be replicated in the larger Phase 2b/3 trial.
• Patients with intermediate dry AMD should not delay seeking standard care (AREDS2 supplements, regular monitoring) in anticipation of risuteganib availability.

These warnings are based on available preclinical and clinical data. The absence of a warning does not indicate safety. Consult qualified professionals before making any decisions regarding peptide research.

Related Reading#

• Risuteganib overview and research guide
• Risuteganib side effects profile
• Risuteganib research evidence